Hal Barron and Emma Walmsley
February 9, 2022 01:17 PM ESTUpdated 01:59 PM
R&D

Hal Bar­ron’s swan song as GSK R&D chief ends with a promise: The best is yet to come

John Carroll

Editor & Founder

Amber Tong

Em­ma Walm­s­ley has one cen­tral mes­sage for to­day’s Q4 up­date: Start­ing in 2022, Glax­o­SmithK­line will be­gin a new era of growth.

The long-an­tic­i­pat­ed spin­off of …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Up­dat­ed: Am­gen obe­si­ty shot shows 20% weight loss, but dos­ing ques­tions hang over read­out

Sarep­ta li­cens­es Ar­row­head­'s RNA-based rare dis­ease pipeline, promis­ing big biobucks

The Biden ad­min­is­tra­tion wants Medicare and Med­ic­aid to cov­er GLP-1s. Will the Trump White House al­low it?

Up­dat­ed: Roche buys out CAR-T part­ner Po­sei­da for $1B up­front

Food al­ler­gy biotech Al­ladapt clos­es af­ter Phase 3 talks with FDA

Ax­some moves to­ward NDA fil­ing for nar­colep­sy drug fol­low­ing pos­i­tive Phase 3 da­ta

A service from the Financial Times